Profile: Bristol Myers Squibb and Pfizer Alliance


In 2007, Pfizer and Bristol Myers Squibb entered a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol Myers Squibb. This global alliance combines Bristol Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.

  • Annie Herrington
    PharmD, BCPS, US Medical Affairs CV/Metabolic & Core Brands Team Lead, Pfizer Biopharmaceutical Group
  • Birgit Roy
    Senior Director, Worldwide Professional Societies and Associations Team, Bristol Myers Squibb
  • George H Sands
    MD FAAN, FAHA, Senior Medical Director, US Medical Affairs, Internal Medicine, Pfizer Biopharmaceutical Group
  • Kristie Yadro
    PharmD, Director, Worldwide CV, Professional Societies and Alliances, Bristol Myers Squibb
[ Feedback → ]